Pfizer’s Abrocitinib yields positive results in phase 3 moderate to severe AD trial

This article was originally published here

B7451012 was a randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of two doses (100mg and 200mg once daily) of abrocitinib monotherapy over 12

The post Pfizer’s Abrocitinib yields positive results in phase 3 moderate to severe AD trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply